Our complete response, our bisPSMA technology delivering more product to the tumour, our supply chain & logistics, our Day 2 diagnostic capability, our pipeline including SAR Bombesin and SARtate all probably make the valuation much higher. I believe Cu64-67 pair with the bisPSMA tech is a match made in heaven and values us at the top end of current radiopharma deals. It’s a matter of right place at the right time. Time will tell.
In the aus biz interview Alan said we can fix what’s broken with Pluvicto - make of it what you will.
No advice.
CU6 - ASX Charts, page-666
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.85 |
Change
-0.260(4.26%) |
Mkt cap ! $1.823B | |||
| Open | High | Low | Value | Volume |
| $6.11 | $6.39 | $5.63 | $10.51M | 1.750M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4103 | $5.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.88 | 175 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |